QC
PLX icon

Quantessence Capital’s Protalix BioTherapeutics PLX Stock Holding History

Quantessence Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,243
Closed -$131K – 379
2025
Q1 		$131K Buy
+51,243
New +$122K 0.03% 296

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Quantessence Capital's PLX Position: Q2 2025 in Review

Quantessence Capital sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 51,243 shares — an estimated $131K sold.

Quantessence Capital first reported a position in PLX in Q1 2025 and held it in 1 quarter. The position peaked at $131K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Quantessence Capital reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 51,243 Protalix BioTherapeutics shares in Q2 2025, an estimated $131K.
  • Quantessence Capital first reported a position in Protalix BioTherapeutics in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Protalix BioTherapeutics position peaked at $131K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.